EpiCast Report: Healthcare-Associated Gram-Negative Infections - Epidemiology Forecast to 2026

EpiCast Report: Healthcare-Associated Gram-Negative Infections - Epidemiology Forecast to 2026

Summary

Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems (Peleg et al., 2010). HAIs occur in hospitalized patients, and are not present at the time of admission (NHSN, 2017). Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs) (Magill et al., 2014). Magill and colleagues estimate that one in 25 hospitalized patients will develop an HAI (Magill et al., 2014).

Infections caused by Gram-negative bacteria are of particular public health concern, since they are at the root of approximately 30-70% of HAIs across the globe (ECDC, 2013; Kim et al., 2000; Peleg et al., 2010; Solis-Hernandez et al., 2015; Weiner et al., 2016). Gram-negative bacteria are highly efficient at altering their genetic makeup to combat antibiotics, and often use a variety of mechanisms against the same antibiotic, or one mechanism against several antibiotics (Peleg et al., 2010).

Epidemiologists forecast that the suspected incident cases of CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an Annual Growth Rate (AGR) of 0.60% per year over the next 10 years. In the 7MM, the US will have the highest number of suspected incident cases, while Japan will have the lowest number of suspected incident cases. Across the 7MM, the most common infection site in suspected HAIs is SSI in the US, Germany, Spain, and Japan. However, in France, Italy, and the UK, HAP/VAPs are the most common infection site in suspected HAIs.

Epidemiologists also forecast that the diagnosed incident cases of Gram-negative CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an AGR of 0.55% per year over the next 10 years. In the 7MM, the US will have the highest number of diagnosed incident cases, with 505,544 in 2016, while Japan will have the lowest number of diagnosed incident cases.

The report EpiCast Report: Healthcare-Associated Gram-Negative Infections - Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and global and historical trends for Gram-negative HAIs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of HAIs and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites (CAUTI, CLABSI, HAP/VAP, SSI).

In depth, this report provides the following -

• The Healthcare-Associated Gram-Negative Infections epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Scope

• The Healthcare-Associated Gram-Negative Infections EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of healthcare-associated Gram-negative infections in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of healthcare-associated infections (HAIs) and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites: catheter-associated urinary tract infection (CAUTI), central line-associated blood stream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infection site-specific diagnosed incident cases of Gram-negative HAIs are further segmented by causative agent (Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa).
• The Healthcare-Associated Gram-Negative Infections epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Healthcare-Associated Gram-Negative Infections EpiCast report will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global Gram-negative HAI market.
• Quantify patient populations in the global Gram-negative HAI market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gram-negative HAI therapeutics in each of the markets covered.
• Identify the percentage of suspected and diagnosed incident cases of Gram-negative HAIs by various clinical segmentations.